Castle Biosciences Inc expected to post a loss of 27 cents a share - Earnings Preview

Castle Biosciences

03/08/2024 03:04

* Castle Biosciences Inc  CSTL.OQ   CSTL.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 5
for the period ending June 30 2024
    * The Friendswood Texas-based  company is expected to report
a
38.3% increase in revenue to $69.341 million from $50.14 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Castle Biosciences Inc
is for
a loss of 27 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $34.00​, above​ its last closing price
of $22.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.30       -0.33      -0.09     Beat    72.9
 Dec. 31 2024  -0.48       -0.54      -0.10     Beat    81.4
 Sep. 30 2023  -0.74       -0.76      -0.26     Beat    66​
 Jun. 30 2023  -0.91       -0.91      -0.70     Beat    23.5
 ​​Mar.        -0.91       -0.89      -1.10     Missed  -23.4
 31 2023                                                
 Dec. 31 2022  -0.85       -0.84      -0.78     Beat    6.9​
 Sep. 30 2022  -0.92       -0.88      -0.77     Beat    12.5
 Jun. 30 2022  -0.77       -0.76      -0.06     Beat    92.1
 This summary was machine generated August 3 at 02:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)